These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32961833)

  • 1. Evaluation of Intravenous Fosfomycin Disodium Dosing Regimens in Critically Ill Patients for Treatment of Carbapenem-Resistant Enterobacterales Infections Using Monte Carlo Simulation.
    Leelawattanachai P; Wattanavijitkul T; Paiboonvong T; Plongla R; Chatsuwan T; Usayaporn S; Nosoongnoen W; Montakantikul P
    Antibiotics (Basel); 2020 Sep; 9(9):. PubMed ID: 32961833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant
    Kanchanasurakit S; Santimaleeworagun W; McPherson CE; Piriyachananusorn N; Boonsong B; Katwilat P; Saokaew S
    Infect Chemother; 2020 Dec; 52(4):516-529. PubMed ID: 33124216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli.
    Merino-Bohórquez V; Docobo-Pérez F; Sojo J; Morales I; Lupión C; Martín D; Cameán M; Hope W; Pascual Á; Rodríguez-Baño J
    Clin Microbiol Infect; 2018 Nov; 24(11):1177-1183. PubMed ID: 29649596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Monte Carlo Simulation of Three Antimicrobials for Empiric Treatment of Adult Bloodstream Infections With Carbapenem-Resistant Enterobacterales in China.
    Zou D; Yao G; Shen C; Ji J; Ying C; Wang P; Liu Z; Wang J; Jin Y; Xiao Y
    Front Microbiol; 2021; 12():738812. PubMed ID: 34899628
    [No Abstract]   [Full Text] [Related]  

  • 5. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant
    Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W
    Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation.
    Asuphon O; Montakantikul P; Houngsaitong J; Kiratisin P; Sonthisombat P
    Int J Infect Dis; 2016 Sep; 50():23-9. PubMed ID: 27418581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the Susceptibility of Clinical Gram-Negative and Gram-Positive Bacterial Strains to Fosfomycin and Significance of This Antibiotic in Infection Treatment.
    Kowalska-Krochmal B; Mączyńska B; Rurańska-Smutnicka D; Secewicz A; Krochmal G; Bartelak M; Górzyńska A; Laufer K; Woronowicz K; Łubniewska J; Łappo J; Czwartos M; Dudek-Wicher R
    Pathogens; 2022 Nov; 11(12):. PubMed ID: 36558775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amoxicillin and penicillin G dosing in pediatric community-acquired pneumococcal pneumonia in the era of conjugate pneumococcal vaccines.
    Huynh D; Tung N; Dam Q; Tran T; Hulten KG; Harrison CJ; Kaplan SL; Nguyen A; Do TH; Setty A; Le J
    Pharmacotherapy; 2022 Dec; ():. PubMed ID: 36571459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Evaluation of Meropenem Dosing Regimens Against ESBL-Producing
    Win EE; Htun KW; Tragulpiankit P; Tangtrakultham S; Montakantikul P
    Infect Drug Resist; 2022; 15():439-453. PubMed ID: 35177911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colistin plus Sulbactam or Fosfomycin against Carbapenem-Resistant
    Saelim W; Changpradub D; Thunyaharn S; Juntanawiwat P; Nulsopapon P; Santimaleeworagun W
    Infect Chemother; 2021 Mar; 53(1):128-140. PubMed ID: 34409786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.
    Fedrigo NH; Mazucheli J; Albiero J; Shinohara DR; Lodi FG; Machado ACDS; Sy SKB; Tognim MCB
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic/Pharmacodynamic (PK/PD) Simulation for Dosage Optimization of Colistin Against Carbapenem-Resistant
    Jitaree K; Sathirakul K; Houngsaitong J; Asuphon O; Saelim W; Thamlikitkul V; Montakantikul P
    Antibiotics (Basel); 2019 Aug; 8(3):. PubMed ID: 31443514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults.
    Kispal B; Walker SAN
    Eur J Clin Pharmacol; 2021 Feb; 77(2):197-205. PubMed ID: 32975650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using Monte Carlo simulation.
    Wang G; Yu W; Cui Y; Shi Q; Huang C; Xiao Y
    BMC Infect Dis; 2021 Mar; 21(1):307. PubMed ID: 33771113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the Dosing Regimens of Daptomycin Based on the Susceptible Dose-Dependent Breakpoint against Vancomycin-Resistant Enterococci Infection.
    Santimaleeworagun W; Changpradub D; Thunyaharn S; Hemapanpairoa J
    Antibiotics (Basel); 2019 Nov; 8(4):. PubMed ID: 31795437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deciphering pharmacokinetics and pharmacodynamics of fosfomycin.
    Rodríguez-Gascón A; Canut-Blasco A
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):19-24. PubMed ID: 31131588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of Linezolid Dosing Regimens for Treatment of Vancomycin-Resistant Enterococci Infection.
    Santimaleeworagun W; Changpradub D; Hemapanpairoa J; Thunyaharn S
    Infect Chemother; 2021 Sep; 53(3):503-511. PubMed ID: 34405596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis.
    Chen CY; Xie M; Gong J; Yu N; Wei R; Lei LL; Zhao SM; Li RM; Dong X; Zhang XL; Zhou Y; Li SL; Cui YM
    Front Pharmacol; 2023; 14():1132367. PubMed ID: 37188268
    [No Abstract]   [Full Text] [Related]  

  • 19. Colistin Dosing Regimens against
    Nguyen VTK; Montakantikul P; Tragulpiankit P; Houngsaitong J; Shuib MF
    Antibiotics (Basel); 2021 May; 10(5):. PubMed ID: 34067716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases.
    Isla A; Canut A; Arribas J; Asín-Prieto E; Rodríguez-Gascón A
    Eur J Clin Microbiol Infect Dis; 2016 Mar; 35(3):511-9. PubMed ID: 26782093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.